Atopic Dermatitis in Dogs: A Comprehensive Management Guide
Canine atopic dermatitis (CAD) is a chronic, genetically predisposed inflammatory skin disease that represents one of the most challenging conditions in veterinary medicine. It cannot be cured, but with modern diagnostic tools and a widening range of treatment options, most affected dogs can achieve an excellent quality of life. This guide explores the condition in depth — from diagnosis to long-term management strategies available to owners across Europe.
Most Affected Breeds
Atopic dermatitis has a clear hereditary component, with certain breeds showing dramatically elevated prevalence:
- West Highland White Terrier — among the highest rates of any breed
- Boxer
- Labrador and Golden Retriever & Cancer: Prevention, Early Detection & The Morris Study">Golden Retriever Health Problems">Golden Retriever Breed Guide">Golden Retriever Shedding Guide">Golden Retriever & Cancer: Prevention, Early Detection & The Morris Study">Golden Retriever Health Problems">Golden Retriever
- Dalmatian
- English Bulldog
- German Shepherd
- Cocker Spaniel
- Shar Pei — frequently severe and difficult to manage
- Shih Tzu and Maltese
Pathophysiology: What Goes Wrong
Atopic dermatitis arises from a combination of a defective skin barrier and a dysregulated immune response. In normal skin, the stratum corneum (the outermost layer) forms an effective barrier against allergen penetration. In atopic dogs, this barrier is structurally deficient — partly due to abnormalities in ceramide composition and intercellular lipid organisation. Allergens penetrate more easily, encounter immune cells beneath the skin surface, and trigger a Th2-skewed immune response characterised by elevated IgE production and interleukin-4, IL-13, and IL-31 signalling. IL-31 is particularly important as the primary itch-signalling cytokine in dogs.
The Favrot Diagnostic Criteria
Because there is no single definitive test for canine atopic dermatitis, diagnosis is based on clinical criteria combined with exclusion of other causes of pruritus. The Favrot criteria, developed through a multicentre European study, provide a validated diagnostic framework. A dog meeting five or more of these eight criteria is likely atopic:
- Onset of signs before three years of age
- Living predominantly indoors
- Pruritus that is initially without lesions (primary itch)
- Front paws affected
- Ear pinnae affected
- Ear margins not affected
- Dorsolumbar area not affected
- Positive response to glucocorticoid therapy
Using five criteria, the Favrot criteria have a sensitivity of 85% and specificity of 79%. They are a clinical tool, not a replacement for full diagnostic work-up.
CADESI Scoring: Measuring Disease Severity
The Canine Atopic Dermatitis Extent and Severity Index (CADESI) is a validated scoring system used by veterinary dermatologists to objectively assess disease severity and monitor response to treatment. The current version (CADESI-04) evaluates erythema (redness), lichenification (skin thickening), and excoriation (self-trauma) at 20 body sites, producing a total score from 0 to 180. CADESI is used in clinical trials to compare treatment efficacy and in specialist practice to guide and monitor treatment decisions.
Establishing the Diagnosis: Ruling Out Other Causes
Before diagnosing atopic dermatitis, other causes of pruritus must be excluded:
- Ectoparasites — Sarcoptes (scabies), Cheyletiella, and fleas must be treated or definitively excluded
- Food allergy — an 8 to 12-week dietary elimination trial should be performed if food allergy is suspected (particularly if symptoms are year-round or if there is concurrent gastrointestinal disease)
- Bacterial and yeast secondary infections — pyoderma and Malassezia dermatitis frequently complicate atopy and must be treated concurrently
Allergen Testing and Immunotherapy
Intradermal allergy testing (IDAT) — the injection of small amounts of allergen extracts into the skin and reading the wheal-and-flare response — is the gold standard for identifying specific allergens. Serum allergen-specific IgE testing (RAST/ELISA) is a less invasive alternative, though results should be interpreted cautiously as specificity is lower.
Allergen-specific immunotherapy (ASIT) involves administering gradually increasing doses of identified allergens — by subcutaneous injection or sublingual drops — to reduce the sensitivity of the immune response over time. It is the only disease-modifying treatment available for canine atopy. Response rates of 50 to 80% are reported, and it is most effective when started early in the disease course. Immunotherapy programmes are available through veterinary dermatology referral centres across Europe, including in the UK, Germany, France, Spain, and the Netherlands.
Pharmacological Management
Cytopoint (Lokivetmab)
Lokivetmab is a canine monoclonal antibody that specifically targets and neutralises IL-31 — the primary itch cytokine in atopic dogs. Given as a monthly subcutaneous injection by a veterinarian, it provides rapid (within 24 hours) and sustained itch relief with an excellent safety profile. It is now widely available across Europe and has become a first-line treatment option for many dogs with CAD.
Apoquel (Oclacitinib)
Oclacitinib is a JAK inhibitor that blocks JAK1 and JAK3 signalling pathways involved in itch and allergic inflammation. It provides rapid itch relief (within 4 hours) and is effective as a long-term daily oral treatment. Licensed in Europe, it is particularly useful for dogs where monthly injection is impractical. Regular blood monitoring is recommended for long-term use.
Ciclosporin (Atopica)
Ciclosporin is a calcineurin inhibitor that suppresses T-lymphocyte-mediated immune responses. It takes four to six weeks to reach full efficacy but provides effective long-term control. Side effects include gastrointestinal upset (often transient), and rare cases of papilloma virus activation. It is available in Europe in capsule form.
Corticosteroids
Short courses of oral prednisolone or methylprednisolone remain effective and inexpensive for managing acute flares, but their significant long-term side effects (polyuria, polydipsia, weight gain, immunosuppression, iatrogenic Cushing's syndrome) preclude them as maintenance therapy. Topical hydrocortisone acetonide sprays (Cortavance) are a lower-risk option for localised lesions.
Skin Barrier Repair
Topical products containing ceramides, essential fatty acids, and humectants help restore skin barrier function and reduce allergen penetration. Used alongside systemic therapy, they can meaningfully reduce disease severity and allow lower doses of immunosuppressive drugs. Prescription veterinary emollients and leave-on conditioners are available through veterinary practices and online suppliers including Zooplus.
The Long-Term Perspective
Atopic dermatitis in dogs requires lifelong management. The goal is not cure but control — achieving a quality of life acceptable to both the dog and its owner. With a structured management plan combining allergen avoidance, skin barrier support, appropriate systemic therapy, and allergen-specific immunotherapy, most atopic dogs live comfortable, happy lives. Working with a veterinary dermatologist for complex or refractory cases significantly improves outcomes.